[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 590
1. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
Genetic Alliance. consumer health - Brain Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


2. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


3. Rozmovits L, Khu KJ, Osman S, Gentili F, Guha A, Bernstein M: Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study. J Neurooncol; 2010 Jan;96(2):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study.
  • Twenty-five semi-structured interviews were conducted with ambulatory adult patients who had undergone surgery for a benign brain tumor, arteriovenous malformation, or unruptured aneurysm.

  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Talking With Your Doctor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jan;71(1):24-6 [11167593.001]
  • [Cites] Heart. 2001 Dec;86(6):626-31 [11711453.001]
  • [Cites] BMJ. 2003 Nov 15;327(7424):1159-61 [14615345.001]
  • [Cites] Br Heart J. 1984 Oct;52(4):468-70 [6477788.001]
  • [Cites] J R Soc Med. 1994 Mar;87(3):149-52 [8158593.001]
  • [Cites] Neurosurgery. 2009 Jan;64(1):40-7; discussion 47 [19145155.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Sep;28(3):407-14 [16055340.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):307-12 [16529133.001]
  • [Cites] J Med Ethics. 2006 Oct;32(10):612-6 [17012508.001]
  • [Cites] Int J Qual Health Care. 2007 Apr;19(2):113-9 [17277008.001]
  • [Cites] N Z Med J. 1998 Sep 11;111(1073):340-2 [9785548.001]
  • (PMID = 19575147.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 77670
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808535
  •  go-up   go-down


Advertisement
4. Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA: Tractographic analysis of historical lesion surgery for depression. Neuropsychopharmacology; 2010 Dec;35(13):2553-63
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various surgical brain ablation procedures for the treatment of refractory depression were developed in the twentieth century.
  • It is possible that the observed clinical improvements of these various surgical procedures may reflect shared influences on presently unspecified brain affect-regulating networks.
  • Such possibilities can now be analyzed using modern brain connectivity procedures such as diffusion tensor imaging (DTI) tractography.
  • Accordingly, modestly sized historical lesions, especially of the anatomical overlap areas, were 'implanted' in brain-MRI scans of 53 healthy subjects.
  • [MeSH-major] Brain / anatomy & histology. Depression / surgery. Neural Pathways / anatomy & histology. Neuroanatomical Tract-Tracing Techniques / methods. Psychosurgery / methods

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Neurosurg Focus. 2008;25(1):E2 [18590379.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1043-9; discussion 1049-52 [11950407.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Sep;42(9):365-71 [12371591.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] Nat Neurosci. 2003 Jul;6(7):750-7 [12808459.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):199-212 [12856488.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):225-35 [12856490.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):234-44 [12890982.001]
  • [Cites] Br J Psychiatry. 1969 Mar;115(520):257-66 [4893673.001]
  • [Cites] Exp Neurol. 1973 Sep;40(3):798-805 [4124980.001]
  • [Cites] Br J Psychiatry. 1973 Aug;123(573):141-8 [4582235.001]
  • [Cites] Med J Aust. 1973 Aug 25;2(8):366-71 [4749527.001]
  • [Cites] Postgrad Med J. 1973 Dec;49(578):860-4 [4618905.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:226-40 [1252686.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(4):175-94 [1842976.001]
  • [Cites] J Clin Psychiatry. 1993 Nov;54(11):405-18 [8270583.001]
  • [Cites] Br J Psychiatry. 1994 Nov;165(5):599-611; discussion 612-3 [7866675.001]
  • [Cites] Annu Rev Psychol. 1995;46:209-35 [7872730.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):103-12 [7711480.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):230-4 [7626968.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Cereb Cortex. 2005 Jan;15(1):31-9 [15238447.001]
  • [Cites] Neuron. 2005 Mar 3;45(5):651-60 [15748841.001]
  • [Cites] Gesnerus. 2005;62(1-2):77-101 [16201322.001]
  • [Cites] Neuroimage. 2006 May 15;31(1):440-57 [16466680.001]
  • [Cites] Stereotact Funct Neurosurg. 2006;84(5-6):228-35 [17063044.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Neuroimage. 2007 May 1;35(4):1531-7 [17391987.001]
  • [Cites] Ann N Y Acad Sci. 2007 May;1104:70-88 [17344522.001]
  • [Cites] Brain Res Rev. 2007 Dec;56(2):283-321 [17905440.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(2):368-77 [17429407.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):138-42 [18068369.001]
  • [Cites] CNS Spectr. 2008 Aug;13(8):663-81 [18704022.001]
  • [Cites] Biol Psychiatry. 2008 Sep 15;64(6):461-7 [18639234.001]
  • [Cites] Psychiatry Res. 2008 Nov 30;164(2):132-42 [18945599.001]
  • [Cites] Nat Neurosci. 2009 Jan;12(1):32-4 [19029888.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):276-82 [19013554.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):717-25 [19339763.001]
  • [Cites] Science. 2009 Apr 17;324(5925):354-9 [19299587.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1106-14; discussion 1114-5 [19487890.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1209-15 [19480538.001]
  • [Cites] Biol Psychiatry. 2010 Jan 15;67(2):117-24 [19819426.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):4-26 [19812543.001]
  • [Cites] CNS Drugs. 2010 Feb;24(2):131-61 [20088620.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):748-51 [20346752.001]
  • [Cites] J Psychiatr Res. 2010 Aug;44(11):683-7 [20096858.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):570-82 [18255316.001]
  • [Cites] Biol Psychiatry. 2008 Apr 1;63(7):670-7 [17916331.001]
  • [Cites] Cereb Cortex. 2008 Jun;18(6):1374-83 [17928332.001]
  • [Cites] J Nerv Ment Dis. 2008 May;196(5):405-10 [18477883.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322 [11545704.001]
  • (PMID = 20736994.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3055575
  •  go-up   go-down


5. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


6. Guan M, Chen Y: Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol; 2005 Nov;58(11):1175-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
  • N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.
  • AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.
  • RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):165-70 [11801554.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):343-5 [11859417.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Acta Oncol. 2002;41(6):550-5 [12546528.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):174-81 [12806379.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):215-20 [12865464.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):162-6 [14618632.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1337-41 [15138575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6905-11 [15501968.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2076-7 [9605745.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1154-8 [10393724.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):464-9 [11101847.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Chin Med J (Engl). 2000 Apr;113(4):299-302 [11775222.001]
  • (PMID = 16254107.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1770779
  •  go-up   go-down


7. Meningioma. Understanding this usually benign brain tumor. Mayo Clin Health Lett; 2010 Jul;28(7):4-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma. Understanding this usually benign brain tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Health Knowledge, Attitudes, Practice. Meningioma / diagnosis. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799379.001).
  • [ISSN] 0741-6245
  • [Journal-full-title] Mayo Clinic health letter (English ed.)
  • [ISO-abbreviation] Mayo Clin Health Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140507.001).
  • [ISSN] 0924-9338
  • [Journal-full-title] European psychiatry : the journal of the Association of European Psychiatrists
  • [ISO-abbreviation] Eur. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Aihara N, Mase M, Yamada K: [Treatment of benign brain tumor in elderly patients]. Nihon Rinsho; 2005 Sep;63 Suppl 9:600-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of benign brain tumor in elderly patients].
  • [MeSH-major] Adenoma / therapy. Cochlear Nerve / surgery. Cranial Nerve Neoplasms / therapy. Pituitary Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201588.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  • [Number-of-references] 13
  •  go-up   go-down


11. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


12. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


13. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


14. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


15. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci; 2006 Dec;256(8):516-21
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess the long-term survival of brain tumor patients, and in particular to evaluate the relation of quality of life (QOL) to survival among low-grade glioma patients.
  • METHODS: The postoperative survival of 101 brain tumor patients was followed from surgery (1990-1992) until the end of the year 2003.
  • RESULTS: The mean survival times in years (SD) were significantly related to tumor malignancy, being the shortest, 1.9 (0.6), for patients with high-grade gliomas, while patients with low-grade gliomas or a benign brain tumor had mean survival times of 9.1 (1.0) and 11.6 (0.5), respectively.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / psychology. Depressive Disorder / mortality. Depressive Disorder / psychology. Glioma / mortality. Glioma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / mortality. Postoperative Complications / psychology. Prognosis. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):269-82 [12893103.001]
  • [Cites] J Clin Oncol. 1996 Jan;14 (1):171-5 [8558193.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1999 Apr;60(4):217-34 [10397403.001]
  • [Cites] J Am Geriatr Soc. 2000 Dec;48(12):1707-13 [11129765.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):373-7 [11861699.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):683-94 [10784457.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] Ann Med. 2001 Jul;33(5):328-36 [11491191.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):562-8 [15774446.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17 [15694227.001]
  • [Cites] Acta Neurol Scand. 1990 Jun;81(6):541-9 [2220313.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7 [14744282.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3381-8 [15310784.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):356-64 [2299375.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):495-504; discussion 495-504 [16145528.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):177-80 [12893090.001]
  • [Cites] Pancreas. 2006 Jan;32(1):58-61 [16340745.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1234-41; discussion 1241-2 [15918939.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):617-25 [15465465.001]
  • [Cites] Strahlenther Onkol. 2003 Jan;179(1):8-15 [12540979.001]
  • [Cites] Med Hypotheses. 1998 Oct;51(4):309-14 [9824837.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1895-903 [11576846.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1710-4 [16098457.001]
  • (PMID = 16960653.001).
  • [ISSN] 0940-1334
  • [Journal-full-title] European archives of psychiatry and clinical neuroscience
  • [ISO-abbreviation] Eur Arch Psychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


16. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A: Potential Role of 18Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiating Benign Neurofibroma from Malignant Peripheral Nerve Sheath Tumor Associated with Neurofibromatosis 1. Neurosurgery; 2009 Oct 01;65(suppl_4):A160-A170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential Role of 18Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiating Benign Neurofibroma from Malignant Peripheral Nerve Sheath Tumor Associated with Neurofibromatosis 1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180848.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chen H, Sun XF, Wu JS: [Clinicopathologic study of subependymal giant cell astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):656-9
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor often occurred in the lateral ventricles (16/18, 88.9%).
  • CONCLUSIONS: Subependymal giant cell astrocytoma is a benign brain tumor with distinctive histopathologic features.
  • The tumor typically affects children and young adults.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374208.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


18. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


19. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Tumors located in the cavernous sinus, tuberculum sellae, foramen magnum, ventricles, and petroclival region were excluded.
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Blackburn W, Leung G, Morash C: Brain Tumour Foundation Award 2007. Glomus jugulare tumours: are they really so benign? Can J Neurosci Nurs; 2007;29(2):21-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain Tumour Foundation Award 2007. Glomus jugulare tumours: are they really so benign?
  • Glomus jugulare tumours are rare, hypervascular and usually benign tumours involving the skull base.
  • Diagnosis can be significantly delayed due to the slow and insidious clinical presentation.
  • These complications are linked to the location and vascular nature of the tumour.
  • [MeSH-major] Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / therapy. Nurse's Role. Perioperative Care
  • [MeSH-minor] Angiography, Digital Subtraction. Diagnosis, Differential. Early Diagnosis. Embolization, Therapeutic / methods. Embolization, Therapeutic / nursing. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Middle Aged. Patient Care Team / organization & administration. Prevalence. Prognosis. Rare Diseases. Risk Factors. Tinnitus / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240628.001).
  • [ISSN] 1913-7176
  • [Journal-full-title] Canadian journal of neuroscience nursing
  • [ISO-abbreviation] Can J Neurosci Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 42
  •  go-up   go-down


23. Romero-Rojas AE, Díaz-Pérez JA, Lozano-Castillo A: [Malignant peripheric nerve sheath tumor of the orbit: first description of orbital location in a patient with NF1]. Neurocirugia (Astur); 2010 Feb;21(1):37-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peripheric nerve sheath tumor of the orbit: first description of orbital location in a patient with NF1].
  • [Transliterated title] Tumor maligno de la vaina del nervio periférico (MPNST) glandular de la órbita: primera descripción de la literatura de localización orbitaria en un paciente con neurofibromatosis tipo 1.
  • INTRODUCTION: The malignant peripheric nerve sheath tumor (MPNST), is a malignant neoplastic lesion originated in Schwann cells of the lining sheath of peripheral nerves.
  • This neoplasia may appear with benign or malignant heterologous components, with divergent differentiation, as the glandular one.
  • CLINICAL CASE: Nine year old male, with a base diagnosis of NF1, who had exophthalmos, retro-ocular pain, headache, facial asymmetry and descent of the right eyeball, that started 1 year earlier.
  • This patient showed in the Computed Tomography an Magnetic Resonance, a well delimited, lobulated, solid mass at the eyeball, which extended to the fontal and temporal brain parenchyma.
  • The diagnosis of Glandular MPNST was made.
  • This extremely uncommon neoplasia must be taken into account, in the study of biphasic malignant lesions, as its diagnosis is of great importance because of the bad prognosis of the affected patients.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Orbital Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186373.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors.
  • The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this context, high-resolution magic-angle spinning (HR-MAS) spectroscopy of intact tissue from brain tumor biopsies has shown great potential as a support diagnostic tool.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Glutamine and glutamate, which are related to glutathione metabolism and have been associated with tumor recurrence, are also increased in atypical meningiomas.
  • Other metabolites associated with tumor malignancy that show statistically significant differences between benign and atypical meningiomas include phosphocholine and phosphoethanolamine.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Principal Component Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A; 2005 Jul 5;102(27):9601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.
  • There are numerous studies on the immune response against malignant human tumors.
  • This study was aimed to address the complexity and specificity of humoral immune response against a benign human tumor.
  • We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library.
  • We detected 17 antigens exclusively with patient sera, including 12 sera that were reactive against KIAA1344, 9 against natural killer tumor recognition (NKTR), and 7 against SRY (sex determining region Y)-box2 (SOX2).
  • Our results show a highly complex but specific humoral immune response against a benign tumor with a distinct serum reactivity pattern and a decline of complexity with malignancy.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antibody Formation / immunology. Antigens, Neoplasm / immunology. Meningioma / immunology
  • [MeSH-minor] Antibody Specificity. Brain / metabolism. DNA Primers. Discriminant Analysis. Gene Library. Humans. Meninges / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Serologic Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3560-8 [10589772.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):815-26 [10499920.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 11;283(3):634-40 [11341771.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):830-8 [11785977.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):239-47 [11803467.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5956-63 [14634107.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):257-63 [14719100.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1420-7 [14691456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):51-60 [15305375.001]
  • [Cites] Hum Genet. 1987 Dec;77(4):349-51 [2891603.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6 [8421688.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):686-96 [8373407.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1015-24 [8862517.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2031-41 [9356211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Hum Mol Genet. 1998 Nov;7(12):1859-72 [9811929.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 [10760287.001]
  • (PMID = 15983380.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1172238
  •  go-up   go-down


26. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


27. Aggarwal S, Subberwal M, Kumar S, Sharma M: Brain tumor and role of beta-carotene, a-tocopherol, superoxide dismutase and glutathione peroxidase. J Cancer Res Ther; 2006 Jan-Mar;2(1):24-7
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor and role of beta-carotene, a-tocopherol, superoxide dismutase and glutathione peroxidase.
  • The erythrocyte levels of the antioxidant enzymes SOD and GPx, and serum levels of antioxidants vitamins beta-carotene and beta-tocopherol were estimated in various types of brain tumors, and were compared with the levels in controls.
  • Statistically significant (P<.001) diminished levels of beta-carotene, beta-tocopherol, SOD and GPx, were observed in all the brain tumor patients as compared to controls.
  • Malignant tumor also showed a relative decrease in antioxidant levels as compared to benign tumors.
  • Comparison of histopathological sections of brain tumors also suggested a inverse relationship between antioxidant level and grades of malignancy.
  • Marked decrease in antioxidant levels may have a role in genesis of considerable oxidative stress in brain tumors.
  • Furthermore, the degree of decline in antioxidant levels may indicate severity of malignancy in brain tumors.
  • [MeSH-major] Antioxidants / analysis. Brain Neoplasms / blood. Glutathione Peroxidase / blood. Superoxide Dismutase / blood. alpha-Tocopherol / blood. beta Carotene / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Chemistry / physiology. Child. Female. Humans. Male. Middle Aged. Oxidative Stress / physiology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998669.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 01YAE03M7J / beta Carotene; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


28. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P: Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med; 2007;9(2):117-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor formation in tuberous sclerosis depends on Erk activation.
  • Tuberous sclerosis (TS) is an autosomal dominant disease associated with the formation of usually benign tumors or hamartomas.
  • Here, we show for the first time that in all four brain lesions and one angiomyolipoma from TS patients both extracellular signal-regulated kinase (Erk) and p90 ribosomal S6 kinase 1 activation as well as Erk-dependent phosphorylation of p70 ribosomal S6 kinase 1 are markedly elevated whereas Akt, participating in the classical pathway of mammalian target of rapamycin activation is not always activated.
  • [MeSH-major] Brain Neoplasms / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Tuberous Sclerosis / pathology

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):658-65 [12172554.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28130-8 [12740386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2697-704 [15517874.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94 [15342917.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Dec;43(12):616-8 [14723270.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35364-70 [12167664.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3708-17 [9632753.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):503-10 [10805093.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7652-6 [14633685.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43871-8 [11571286.001]
  • [Cites] Cell Mol Neurobiol. 2005 Aug;25(5):795-805 [16133934.001]
  • [Cites] Epilepsia. 2004 Dec;45(12 ):1525-30 [15571510.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Brain Dev. 2001 Nov;23(7):508-15 [11701246.001]
  • [Cites] J Child Neurol. 2000 Oct;15(10):652-9 [11063078.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Przegl Lek. 2001;58 Suppl 1:12-5 [11355103.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1153-62 [15793295.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3469-75 [12960139.001]
  • [Cites] Hum Mol Genet. 2005 Feb 1;14(3):429-35 [15601645.001]
  • [Cites] Mol Cell Biol. 1984 Aug;4(8):1577-82 [6092920.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):818-26 [15963462.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2479-84 [15466161.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):1-5 [16206276.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1293-5 [15477556.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]
  • (PMID = 17627032.001).
  • [ISSN] 1535-1084
  • [Journal-full-title] Neuromolecular medicine
  • [ISO-abbreviation] Neuromolecular Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / U 0126; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


29. Callu D, Viguier D, Laroussinie F, Puget S, Boddaert N, Kieffer V, Piana H, Escolano S, Renier D, Sainte-Rose C, Grill J, Dellatolas G: Cognitive and academic outcome after benign or malignant cerebellar tumor in children. Cogn Behav Neurol; 2009 Dec;22(4):270-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive and academic outcome after benign or malignant cerebellar tumor in children.
  • OBJECTIVE: To examine the impact of malignancy and location of the cerebellar tumor on motor, cognitive, and psychologic outcome.
  • BACKGROUND: Although many studies focus on long-term outcome after cerebellar tumor treatment in childhood, the impact of its precise location remains unclear.
  • PATIENTS AND METHODS: Children, aged from 6 to 13 years, with a cerebellar malignant tumor (MT; MT group, n=20) or a cerebellar benign tumor (BT; BT group, n=19) were examined at least 6 months after the end of treatment using the international cooperative ataxia rating scale, the Purdue pegboard for manual skill assessment and the age-adapted Weschler scale.
  • Structural changes in brain anatomy were evaluated and parents and teachers answered 2 independent questionnaires.
  • RESULTS: Parents and teachers reported high rate of learning and academic difficulties, but without any difference with respect to the type of tumor.
  • [MeSH-major] Achievement. Cerebellar Neoplasms / therapy. Cognition. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996881.001).
  • [ISSN] 1543-3641
  • [Journal-full-title] Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
  • [ISO-abbreviation] Cogn Behav Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648771.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 57
  •  go-up   go-down


31. Suma HR, Prabhu K, Shenoy RP, Annaswamy R, Rao S, Rao A: Estimation of salivary protein thiols and total antioxidant power of saliva in brain tumor patients. J Cancer Res Ther; 2010 Jul-Sep;6(3):278-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of salivary protein thiols and total antioxidant power of saliva in brain tumor patients.
  • Brain is considered abnormally sensitive to oxidative damage as brain tissue has high rate of oxygen consumption, high lipid content and relatively low antioxidant defenses, compared to other tissues.
  • RESULTS: The mean values of salivary flow rate and pH were significantly decreased among malignant and benign tumor patients whereas the salivary osmolality was significantly increased in both the groups of patients.
  • The mean values of salivary FRAP were significantly reduced among malignant and benign tumor patients.
  • CONCLUSION: Hence with these observations it can be concluded that in saliva, besides the physical characteristics, salivary FRAP and protein thiol levels are appropriate indicators of the antioxidant status in brain tumor patients.
  • [MeSH-major] Antioxidants / metabolism. Brain Neoplasms / metabolism. Salivary Proteins and Peptides / metabolism. Sulfhydryl Compounds / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119253.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Salivary Proteins and Peptides; 0 / Sulfhydryl Compounds
  •  go-up   go-down


32. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


33. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • The patients with recurrent or residual tumors did not always receive adjuvant treatment.
  • Including subtotally treated tumors, the retreatment rate was 9.8% at 10 years and 25.6% at 20 years.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • While randomized comparisons assessing tumor recurrence, quality of life, or survival are the ideal means of comparing treatments, it can be difficult to recruit patients to such trials and lengthy follow-up periods are needed because of the slowly progressive natural history of these tumors.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Evidence-Based Medicine
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


35. Deryugina EI, Quigley JP: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta; 2010 Jan;1803(1):103-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.
  • A number of extensive reviews are available discussing the roles of MMPs in various aspects of cancer progression from benign tumor formation to overt cancer present with deadly metastases.
  • This review will focus specifically on the evidence functionally linking the MMPs and tumor-induced angiogenesis in various in vivo models.
  • Emphasis has been placed on the cellular origin of the MMPs in tumor tissue, the requirement of proMMP activation and the resulting proteolytic activity for the induction and progression of tumor angiogenesis, and the pleiotropic roles for some of the MMPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):179-91 [17030988.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6965-72 [15466188.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9 [1302560.001]
  • [Cites] J Cell Biol. 1993 Sep;122(6):1351-9 [8376467.001]
  • [Cites] Hybridoma. 1993 Aug;12(4):349-63 [8244415.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Microvasc Res. 1994 Jan;47(1):31-40 [7517489.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] Cell. 1997 Mar 21;88(6):801-10 [9118223.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1534-45 [9119997.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):345-55 [9354769.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1773-84 [9645358.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):757-65 [9736026.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1736-46 [18988801.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1119-30 [19005674.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):809-13 [18997771.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):814-8 [18997773.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):21-34 [19111878.001]
  • [Cites] Matrix Biol. 2009 Jan;28(1):3-10 [19010413.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):399-408 [19188491.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):222-31 [19217424.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1517-26 [19208838.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cell. 2009 Mar 6;136(5):839-51 [19217150.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):381-97 [18958576.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):11-9 [19332889.001]
  • [Cites] Int J Exp Pathol. 2009 Jun;90(3):222-31 [19563607.001]
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25854-66 [19608737.001]
  • [Cites] Curr Opin Cell Biol. 2009 Oct;21(5):645-53 [19616423.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] FASEB J. 2005 Feb;19(2):234-6 [15550552.001]
  • [Cites] Breast Dis. 2004;20:145-53 [15687715.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):265-72 [15781313.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):979-91 [15805464.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Circ Res. 2005 May 13;96(9):930-8 [15890980.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):681-91 [15911882.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8 [15979458.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):997-1002 [16162976.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Cell Mol Med. 2002 Jul-Sep;6(3):439-46 [12417062.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2454-61 [12750266.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66 [12784994.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:49-60 [12799282.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):366-75 [12837607.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Blood. 2006 Jan 1;107(1):317-27 [16174763.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):259-66 [16397239.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):310-8 [16406506.001]
  • [Cites] Nat Methods. 2006 Apr;3(4):259-61 [16554829.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):728-34 [16524717.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):77-86 [16680574.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):812-7 [16627996.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5234-41 [16707448.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6149-55 [16778188.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):159-66 [16857321.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2580-91 [17392479.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Bioessays. 2007 Nov;29(11):1159-68 [17935210.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4222-31 [17699594.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24 [17717634.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8454-65 [17908800.001]
  • [Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] Science. 2008 Jan 11;319(5860):163-4 [18187643.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):181-3 [18328420.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):197-203 [18391785.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):329-40 [18392134.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):203-12 [18079100.001]
  • [Cites] Annu Rev Biochem. 2008;77:383-414 [18366325.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17740-8 [18441011.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):144-53 [18556780.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6251-9 [18676849.001]
  • [Cites] Cell. 2008 Aug 22;134(4):679-91 [18724940.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):30433-7 [18650443.001]
  • [Cites] Methods Enzymol. 2008;444:21-41 [19007659.001]
  • [Cites] Methods Enzymol. 2008;444:255-69 [19007668.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2108-14 [18772495.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Brain. 2003 Dec;126(Pt 12):2738-49 [14506071.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5370-5 [14638740.001]
  • [Cites] Blood. 2004 Jan 1;103(1):110-9 [12958067.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):221-2 [14687614.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):262-8 [14670843.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1687-94 [14996728.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):109-17 [15034802.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57 [15075244.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):11-9 [15137053.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):711-22 [15150280.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5304-13 [15169894.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2202-7 [10681423.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1641-6 [9811357.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] APMIS. 1999 Jan;107(1):38-44 [10190278.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):122-30 [10388526.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3964-72 [10406801.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1292-8 [15516694.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27633-45 [15066996.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1102-13 [10713697.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):15-23 [10728589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7 [10737763.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1647-54 [10815882.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26411-5 [10827175.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):73-84 [11010812.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Hybridoma. 2000 Oct;19(5):375-85 [11128027.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):109-20 [11191049.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 11;1499(1-2):19-33 [11118636.001]
  • [Cites] Methods Mol Biol. 2001;151:411-5 [11217316.001]
  • [Cites] Exp Cell Res. 2001 Feb 15;263(2):209-23 [11161720.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):853-9 [11222550.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2323-32 [11290594.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):463-73 [11401482.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):175-82 [11597792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Radiology. 2001 Nov;221(2):523-9 [11687699.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):272-81 [11803470.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):580-8 [11809713.001]
  • [Cites] Acta Haematol. 2001;106(4):162-9 [11815713.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7377-85 [11741954.001]
  • [Cites] FASEB J. 2002 Mar;16(3):379-89 [11874987.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9749-56 [11724803.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):207-14 [11983094.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36288-95 [12114504.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5580-9 [12359771.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5060-4 [12941835.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3739-49 [12950257.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1183-96 [16997855.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1773(3):400-7 [17187878.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6899-905 [17204469.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):611-23 [17200105.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1607-14 [17405818.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):444-8 [17466902.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4353-63 [17483349.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3068-78 [17505010.001]
  • (PMID = 19800930.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105412; United States / NCI NIH HHS / CA / R01 CA055852-16; United States / NCI NIH HHS / CA / CA055852-16; United States / NCI NIH HHS / CA / R01 CA055852; United States / NCI NIH HHS / CA / R01 CA129484
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 240
  • [Other-IDs] NLM/ NIHMS154042; NLM/ PMC2824055
  •  go-up   go-down


36. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M: Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med; 2008 Dec;8(8):711-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of brain tumors personal experience and review of the literature.
  • Non-invasive energy metabolism measurements in brain tumors in vivo are now performed widely as molecular imaging by positron emission tomography.
  • Common clinical indications for molecular imaging of primary brain tumors therefore contain (i) primary brain tumor diagnosis, (ii) identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), and (iii) prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • Molecular imaging may identify early disease and differentiate benign from malignant lesions.
  • Moreover, an early identification of treatment effectiveness could influence patient management by providing objective criteria for evaluation of therapeutic strategies for primary brain tumors.
  • The authors present here illustrative data of PET imaging: the thymidine kinase gene expression in experimentally transplanted F98 gliomas in cat brain indicates, that [(18)F]FHBG visualizes cells expressing TK-GFP gene in transduced gliomas as well as quantities and localizes transduced HSV-1-TK expression if the blood brain barrier is disrupted.
  • The higher uptake of [(18)F]FLT in the wild-type compared to the transduced type may demonstrate the different doubling time of both tumor tissues suggesting different cytosolic thymidine kinase activity.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging
  • [MeSH-minor] Animals. Capillary Permeability. Diagnosis, Differential. Drug Discovery. Gene Expression. Genes, Reporter. Genetic Therapy. Humans. Neovascularization, Pathologic. Positron-Emission Tomography / methods. Signal Transduction. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075670.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase
  • [Number-of-references] 158
  •  go-up   go-down


37. Aoki T, Tashiro Y, Fujita K, Kajiwara M, Matsuda Y: [The evaluation of preoperative and postoperative frontal lobe functions in three operative cases of meningioma]. No Shinkei Geka; 2006 Feb;34(2):161-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of frontal meningioma with their pre- and post-operative evaluations of higher brain functions, especially of frontal lobe functions.
  • All of the cases showed the improvement of the frontal lobe functions after the tumor removal.
  • The evaluations of frontal lobe functions in benign brain tumors such as a meningioma are reported only in a few cases.
  • The evaluations of frontal lobe functions in the operative cases of benign brain tumors provide many interesting and valuable informations about frontal lobe functions.
  • So we must be more interest in evaluations in higher brain functions and accumulate cases for the further analysis of higher brain functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485561.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


39. Zheng X, Liu W, Yang X, Gong J, Shen F, Shen G, Shen H, Zheng X, Fu W: Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region. Minim Invasive Ther Allied Technol; 2007;16(6):363-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region.
  • The objective of the study was to evaluate the effectiveness of the supraorbital "keyhole" approach with endoscope assistance in surgical treatment of benign tumors around the sellar region.
  • Thirty-five patients, including 19 pituitary tumors, 11 craniopharyngiomas and five tuberculum sellae meningiomas, were enrolled in this study.
  • The tumors were resected through an endoscope-assisted supraorbital keyhole approach via a small skin incision within the eyebrow.
  • Complete removal of the sellar region tumors was achieved in all 35 cases by endoscope-assisted supraorbital keyhole approach.
  • There was no patient with evidence of residual or recurrent tumor during the follow-up period.
  • The supraorbital "keyhole" approach with endoscopic assistance in the surgical treatment of benign tumors around the sellar region is an ideal pattern.
  • [MeSH-major] Endoscopy. Neoplasms / surgery. Pituitary Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / surgery. Female. Humans. Length of Stay. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852733.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


41. Kuhn E, Dorji T, Rodriguez J, Rosai J: Extramedullary erythropoiesis in chronic subdural hematoma simulating metastatic small round cell tumor. Int J Surg Pathol; 2007 Jul;15(3):288-91
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary erythropoiesis in chronic subdural hematoma simulating metastatic small round cell tumor.
  • In both cases, the initial favored diagnosis by the submitting pathologists was that of a metastatic malignant tumor, including lymphoma, carcinoma, and malignant melanoma.
  • It is important for surgical pathologists to be aware of this benign process and not to overinterpret it as either a primary or metastatic malignant tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Small Cell / pathology. Erythropoiesis. Hematoma, Subdural, Chronic / pathology. Hematopoiesis, Extramedullary
  • [MeSH-minor] Aged. Antigens, CD34 / genetics. Antigens, CD34 / metabolism. Diagnosis, Differential. Erythropoietin / genetics. Erythropoietin / metabolism. Female. Gene Expression Regulation, Neoplastic. Glycophorin / genetics. Glycophorin / metabolism. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652539.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glycophorin; 11096-26-7 / Erythropoietin
  •  go-up   go-down


42. Scolozzi P, Marret N, Bouzourene H, Luthi F, Bauer J, Jaques B, Lombardi T: Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving the maxillary gingiva. J Oral Pathol Med; 2006 Oct;35(9):579-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed testicular germ cell tumor presenting as metastatic pure choriocarcinoma involving the maxillary gingiva.
  • We are reporting here an unusual case of a 36-year-old man with a mixed testicular germ cell tumor presenting as a metastatic pure choriocarcinoma involving the maxillary gingiva, extending from the first left premolar to the left second maxillary molar, mimicking a 'benign looking' gingival mass.
  • [MeSH-major] Choriocarcinoma / secondary. Gingival Neoplasms / secondary. Mixed Tumor, Malignant / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Maxilla

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968241.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


44. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.
  • Ionizing radiation is an established risk factor for brain tumors, yet quantitative information on the long-term risk of different types of brain tumors is sparse.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The mean estimated radiation dose to the brain was 1.5 Gy.
  • Survival analysis using Poisson regression was performed to estimate the excess relative and absolute risks (ERR, EAR) for brain tumors.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The risk of both types of tumors was positively associated with dose.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods. Tinea Capitis / epidemiology. Tinea Capitis / radiotherapy


45. Settin A, Ali N, Salem FK: Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol; 2008;15(2):15-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in Egyptian cases with brain tumors.
  • Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • To evaluate the association of polymorphisms of cytokine genes with brain tumors in Egyptian patients.
  • This study included 45 cases affected by brain tumors.
  • Their median age was 45, diagnosed as 24 benign cases and 21 malignant cases, and their sex included 20 males and 25 females.
  • Cases affected with benign brain tumors, showed a significant higher frequency of IL-10(-1082) A/A genotype (OR = 8.04, P < 0.001), IL-6(-174) C/C genotype (OR = 6.3, P < 0.001) and TNF-alpha(-308) A/A (OR = 4.7, P < 0.05) with a significant lower frequency of IL-10(-1082) G/A genotype (OR = 0.1, P < 0.001), IL-6(-174) G/C (OR = 0.2, P = 0.001) and TNF-alpha(-308) G/A was found significantly low among the same groups (OR = 0.2, P < 0.001) compared to controls.
  • The frequency of cytokines genotype and allele in malignant brain cases and controls.
  • Comparing studied genotype frequencies among benign and malignant brain tumor cases no significant difference was found in the frequencies of all studied genotypes and alleles with a non significant trend for the benign cases to have higher frequency of IL-10(-1082) AA genotype.
  • In conclusion, cytokine gene polymorphisms have a certain pattern among brain tumor cases and can be considered a genetic marker of potential value in counseling and management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306684.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


46. Cho JM, Ahn JY, Kim SH, Lee KS, Chang JH: An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata. Childs Nerv Syst; 2010 Jun;26(6):853-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata.
  • INTRODUCTION: Endodermal cysts, also known as enterogenous, neurenteric, foregut, epithelial, bronchogenic, or respiratory cysts, are rare benign lesions lined by columnar epithelium of a presumed endodermal origin.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis. Medulla Oblongata
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2011 Jun;27(6):861-2; author reply 863 [21503756.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):401-4; discussion 404-5 [9932896.001]
  • [Cites] AMA Am J Dis Child. 1952 Apr;83(4):500-7 [14902104.001]
  • [Cites] Australas Radiol. 2006 Feb;50(1):59-62 [16499730.001]
  • [Cites] Surg Gynecol Obstet. 1954 Aug;99(2):135-41 [13187191.001]
  • [Cites] Can J Neurol Sci. 1989 May;16(2):206-10 [2731091.001]
  • [Cites] J Neurosurg Spine. 2005 Mar;2(3):372-6 [15796365.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1091-3 [15200128.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):583-7; discussion 587-8 [2034355.001]
  • [Cites] AMA Arch Pathol. 1952 Aug;54(2):132-8 [14943345.001]
  • [Cites] Childs Nerv Syst. 1988 Feb;4(1):47-9 [3401868.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):243-5; discussion 246 [12493126.001]
  • [Cites] Clin Radiol. 1985 May;36(3):245-51 [4064506.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1211-6 [16775266.001]
  • [Cites] J Neurosurg. 1998 Aug;89(2):326-35 [9688132.001]
  • [Cites] Arq Neuropsiquiatr. 1993 Jun;51(2):253-7 [8274091.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):764-7 [10981766.001]
  • [Cites] Pediatr Clin North Am. 1958 May;:457-74 [13542070.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):229-53 [1476931.001]
  • [Cites] Br J Surg. 1954 Mar;41(169):520-33 [13149822.001]
  • [Cites] Neurol Med Chir (Tokyo). 2008 Feb;48(2):86-9 [18296879.001]
  • (PMID = 20217097.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, Zarkovic N: Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori; 2009 Nov-Dec;95(6):762-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain.
  • It results in the production of 4-hydroxynonenal (HNE), which plays a crucial role in hypoxic brain injury, neuronal degeneration and apoptosis.
  • The aim of this study was to evaluate the expression of HNE in 120 astrocytic and 40 ependymal tumors in relation to tumor type, grade of malignancy, angiogenesis, and presence of necrosis and apoptosis.
  • RESULTS: HNE-protein adducts were found in all tumors.
  • The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy.
  • Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01).
  • HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05).
  • HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05).
  • The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas.
  • CONCLUSIONS: LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization.
  • Therefore, HNE might be involved in the damage of brain cells and the induction of malignancy.
  • [MeSH-major] Aldehydes / analysis. Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Lipid Peroxidation. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210242.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Biomarkers, Tumor; 0 / Cross-Linking Reagents; 0 / Neoplasm Proteins; 29343-52-0 / 4-hydroxy-2-nonenal
  •  go-up   go-down


48. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Both subtypes are classified according to the World Health Organization grade I, but their irregular digitate brain infiltration makes any complete surgical resection difficult to obtain.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


49. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


50. Sumiyoshi T, Sumiyoshi C, Nohara S, Hagino H, Hasegawa S, Kuwayama N, Endo S, Kurachi M: Verbal memory deficits in a preadolescent case of lesions of the left parahippocampal gyrus associated with a benign tumor. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun;30(4):733-6
MedlinePlus Health Information. consumer health - Memory.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verbal memory deficits in a preadolescent case of lesions of the left parahippocampal gyrus associated with a benign tumor.
  • Neuropsychological examinations soon after the removal of the tumor showed selective deficits in semantic memory function, as evaluated by the Category Fluency Task and the Wechsler Memory Scale-Revised, while visual memory, attention, and IQ were not affected.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hemangioma, Cavernous / physiopathology. Memory Disorders / pathology. Parahippocampal Gyrus / pathology. Verbal Learning / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442196.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


52. Wang F, Qiao G, Li X, Gui Q: A dysembryoplastic neuroepithelial tumor in the area of the caudate nucleus in a 57-year-old woman: case report. Neurosurgery; 2007 Aug;61(2):E420; discussion E420
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dysembryoplastic neuroepithelial tumor in the area of the caudate nucleus in a 57-year-old woman: case report.
  • OBJECTIVE: Dysembryoplastic neuroepithelial tumors (DNTs) are clinicopathologically unique tumors.
  • DNTs may also arise outside of the cerebral cortex.
  • During a 7-year follow-up period, the tumor did not recur.
  • CONCLUSION: Unlike diffuse gliomas, such as oligodendrogliomas and central neurocytomas, DNTs are benign lesions with a favorable prognosis after surgical resection.
  • [MeSH-major] Brain Neoplasms / pathology. Caudate Nucleus / pathology. Neoplasms, Neuroepithelial / pathology

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762726.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Unlike the abundantly expressed CB1, the CB2 receptor shows a restricted distribution in normal brain.
  • Although brain tumors constitute the second most common malignancy in children and the prevalence of histological types of brain tumors vary significantly between the adult and pediatric populations, cannabinoid receptor expression in pediatric tumors remains unknown.
  • In the present study, we compared the expression of the CB2 receptor in paraffin-embedded sections from primary brain tumors of adult and pediatric patients.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • The high levels of CB2 expression would predestine those tumors to be vulnerable to cannabinoid treatment.
  • In contrast, all examined cases of embryonal tumors (medulloblastoma and S-PNET), the most frequently diagnosed malignant brain tumors in childhood, showed no or trace CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Receptor, Cannabinoid, CB2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


54. Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS, Olivero WC: RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol; 2006 Jun;28(6):1353-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
  • Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas.
  • Intratumoral injections of the plasmid vector expressing siRNA for uPA and uPAR resulted in regression of pre-established, subcutaneous tumors in mice.
  • In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19382-8 [10777511.001]
  • [Cites] Nat Biotechnol. 2000 Aug;18(8):896-8 [10932163.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Am J Manag Care. 2000 Sep;6(14 Suppl):S746-60 [11184072.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1191-200 [11050387.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5839-47 [11059781.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 1;56(1-2):104-32 [11213252.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):2032-43 [11360187.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2519-26 [11489835.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12479-85 [11805108.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Haemostasis. 2001;31 Suppl 1:59 [11990482.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5716-24 [12173041.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):212-6 [12297307.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7824-30 [12420219.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):635-7 [12754523.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Chembiochem. 2005 Feb;6(2):441-3 [15651038.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] BMC Biotechnol. 2003 Nov 6;3:21 [14604435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14883-8 [15466709.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):783-92 [2166055.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):274-81 [1988089.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:13-31 [1339241.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):3983-91 [8076594.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32380-8 [7528215.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] Invasion Metastasis. 1995;15(1-2):34-45 [7672930.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2428-33 [8625323.001]
  • [Cites] Clin Exp Metastasis. 1996 May;14(3):297-307 [8674284.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1996 Sep 13;273(5281):1551-5 [8703217.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):767-77 [9151680.001]
  • [Cites] J Cell Sci. 1997 May;110 ( Pt 9):1091-8 [9175705.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1351-9 [9178895.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):285-96 [9198168.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):58-67 [9202057.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4522-31 [9373263.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1861-72 [9412478.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Clin Exp Metastasis. 1998 May;16(4):353-7 [9626814.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):377-85; discussion 385-6 [9689330.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):854 [9804418.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4499-504 [9891516.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3369-73 [10416596.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8486-96 [15378018.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):123-34 [10591631.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Nov 1;9(21):3147-52 [10560742.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5307-14 [10537314.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Trends Biochem Sci. 2000 Feb;25(2):53-9 [10664583.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):298-304 [10605717.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):371-8 [15372045.001]
  • (PMID = 16685436.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS9142; NLM/ PMC1459538
  •  go-up   go-down


55. Adam C, Polivka M, Carpentier A, George B, Gray F: Papillary glioneuronal tumor: not always a benign tumor? Clin Neuropathol; 2007 May-Jun;26(3):119-24
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary glioneuronal tumor: not always a benign tumor?
  • Papillary glioneuronal tumor (PGNT) is a variant of ganglioglioma, characterized by a pseudopapillary structure with a single pseudostratified layer of small, cuboidal, GFAP-positive cells around hyalinized blood vessels.
  • To date, less than 30 cases have been described with a usually benign course.
  • We report two additional cases: a clinically, radiologically and histopathologically typical tumor in a 38-year-old man and an atypical tumor with histopathological features of anaplasia in a 74-year-old woman.
  • The latter tumor showed the classical pseudopapillary pattern with ganglioid cells and some astrocytes between the papillae, but also had changes suggestive of anaplasia including necrosis, capillary endothelial proliferation, mitoses, dedifferentiation with loss of GFAP expression of the cuboidal cells and increased Ki-67 labeling of over 10%.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157003.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven Vv, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C: The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie; 2005 Jan;28(1):22-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The brain tumor board: lessons to be learned from an interdisciplinary conference.
  • BACKGROUND: The aim of this study is to analyze the work of the interdisciplinary Brain Tumor Board (BTB) which was established at Freiburg University Hospital in 1998.
  • RESULTS: In 79% of the patients, the diagnosis was based on histological findings or a typical radiological appearance of a lesion, or both.
  • This group was composed of 4 subgroups: 28% benign skull base tumors (19% meningiomas, 4% pituitary adenomas, 3% acoustic schwannomas, 2% others), 24% primary brain tumors of glial origin (8% glioblastomas, 12% gliomas other than glioblastomas, 5% oligoastrocytomas or oligodendrogliomas), 19% brain metastases, and 8% other brain or skull base tumors.
  • In 13% of the cases, the exact diagnosis was still unknown when the patient was presented.
  • CONCLUSION: Interdisciplinary care seems to be particularly necessary in patients with benign skull base tumors, gliomas and brain metastases.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials Data Monitoring Committees / statistics & numerical data. Decision Support Systems, Clinical / statistics & numerical data. Outcome Assessment (Health Care). Patient Care Team / statistics & numerical data. Quality Assurance, Health Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15616378.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Muzumdar D, Balasubramaniam S, Jhawar S, Goel A: Massive benign osteoblastoma of the suboccipital bone and foramen magnum region. Pediatr Neurosurg; 2010;46(3):232-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive benign osteoblastoma of the suboccipital bone and foramen magnum region.
  • Benign osteoblastoma is an uncommon primary bone tumor frequently found in the vertebral column and long tubular bones, and rarely occurring in the calvarium.
  • A case of a massive benign osteoblastoma of the suboccipital bone and foramen magnum region in a 9-year-old boy is reported.
  • Computed tomography (CT) of the brain showed a large midline occipital/suboccipital bony lesion extending to either side (R > L) and extending from the torcula till the foramen magnum region, causing moderate obstructive hydrocephalus.
  • The atlas was uninvolved by the tumor.
  • The tumor was completely resected with wide margins via a suboccipital route.
  • The occurrence of benign osteoblastoma in the suboccipital bone and foramen magnum region has not been reported earlier in the pediatric population.
  • [MeSH-major] Foramen Magnum / surgery. Occipital Bone / surgery. Osteoblastoma / surgery. Skull Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21051923.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Jensen TR, Schmainda KM: Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging; 2009 Sep;30(3):481-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided detection of brain tumor invasion using multiparametric MRI.
  • PURPOSE: To determine the potential of using a computer-aided detection method to intelligently distinguish peritumoral edema alone from peritumor edema consisting of tumor using a combination of high-resolution morphological and physiological magnetic resonance imaging (MRI) techniques available on most clinical MRI scanners.
  • MATERIALS AND METHODS: This retrospective study consisted of patients with two types of primary brain tumors: meningiomas (n = 7) and glioblastomas (n = 11).
  • Meningiomas are typically benign and have a clear delineation of tumor and edema.
  • Four classifiers of differing designs were trained using morphological, diffusion-weighted, and perfusion-weighted features derived from MRI to discriminate tumor and edema, tested on edematous regions surrounding tumors, and assessed for their ability to detect nonenhancing tumor invasion.
  • Each classifier was able to identify areas of nonenhancing tumor invasion supported with adjunct images or follow-up studies.
  • CONCLUSION: The combination of features derived from morphological and physiological imaging techniques contains the information necessary for computer-aided detection of tumor invasion and allows for the identification of tumor invasion not previously visualized on morphological, diffusion-weighted, and perfusion-weighted images and maps.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711398.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA028500; United States / NCRR NIH HHS / RR / M01 RR000058; United States / NCI NIH HHS / CA / R21 CA109280; United States / NCI NIH HHS / CA / R01 CA082500; United States / NCRR NIH HHS / RR / M01-RR00058; United States / NCI NIH HHS / CA / R21 CA10928; United States / NCI NIH HHS / CA / R01 CA082500-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS185656; NLM/ PMC4321878
  •  go-up   go-down


59. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • From the prognostic point of view, losses of chromosomes 9, 10, 14, and 18 and del(1p36) were associated with a shorter RFS at 2.5, 5, and 10 years.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


61. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


62. Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ: Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience; 2008 Jan 24;151(2):476-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities.
  • The tumor-suppressor phosphatase with tensin homology (PTEN) is the central negative regulator of the PI3K pathway.
  • Germline PTEN mutations result in cancer predisposition, macrocephaly and benign hamartomas in many tissues, including Lhermitte-Duclos disease, a cerebellar growth disorder.
  • Electron microscopic evaluation revealed enlarged abnormal synaptic structures in the cerebral cortex and cerebellum.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32 [10564676.001]
  • [Cites] Neurosurg Rev. 1980;3(2):151-8 [7231686.001]
  • [Cites] Immunity. 2001 May;14(5):523-34 [11371355.001]
  • [Cites] J Neurochem. 2001 Aug;78(3):468-81 [11483649.001]
  • [Cites] Am J Med Genet. 2001 Aug 8;105(6):521-4 [11496368.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):396-403 [11726926.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):404-11 [11726927.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2186-9 [11691952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):467-72 [11756682.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):29-54 [12086707.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):157-68 [12086874.001]
  • [Cites] Development. 2002 Jul;129(14):3513-22 [12091320.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Development. 2002 Sep;129(17):4159-70 [12163417.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Development. 2003 Apr;130(8):1691-700 [12620992.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12923-8 [14534328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14368-73 [14623952.001]
  • [Cites] Cell. 2003 Dec 26;115(7):893-904 [14697206.001]
  • [Cites] Science. 2004 Feb 20;303(5661):1179-81 [14976311.001]
  • [Cites] J Neurochem. 2004 Apr;89(1):109-18 [15030394.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Science. 2004 Apr 30;304(5671):700-3 [15044753.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1774-83 [15199412.001]
  • [Cites] J Neurosci. 2004 Jul 28;24(30):6724-32 [15282275.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):599-603 [3418394.001]
  • [Cites] Histol Histopathol. 1990 Jul;5(3):329-36 [1724930.001]
  • [Cites] Acta Neuropathol. 1992;84(5):570-3 [1462769.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):223 [9662392.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Am J Med Genet. 1998 Dec 4;80(4):399-402 [9856571.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9760-9 [15525761.001]
  • [Cites] Cell. 2005 Jan 14;120(1):123-35 [15652487.001]
  • [Cites] Glia. 2005 Mar;49(4):542-54 [15578654.001]
  • [Cites] J Neurochem. 2005 Apr;93(1):105-17 [15773910.001]
  • [Cites] Glia. 2005 May;50(3):247-57 [15739189.001]
  • [Cites] Acta Neuropathol. 1983;59(2):88-94 [6837278.001]
  • [Cites] J Med Genet. 2005 Apr;42(4):318-21 [15805158.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3653-62 [16046480.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7426-34 [16288289.001]
  • [Cites] Nat Neurosci. 2005 Dec;8(12):1727-34 [16286931.001]
  • [Cites] J Neurosci. 2005 Dec 7;25(49):11288-99 [16339024.001]
  • [Cites] J Neurosci. 2005 Dec 7;25(49):11300-12 [16339025.001]
  • [Cites] Neurochem Int. 2006 Jan;48(2):114-23 [16239049.001]
  • [Cites] J Cell Sci. 2006 Mar 1;119(Pt 5):951-7 [16495486.001]
  • [Cites] Neuron. 2006 Mar 16;49(6):823-32 [16543131.001]
  • [Cites] Neuron. 2006 May 4;50(3):377-88 [16675393.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18802-15 [16651266.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7429-37 [16885338.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] J Neurosci. 2006 Oct 4;26(40):10199-208 [17021175.001]
  • [Cites] Nat Neurosci. 2006 Dec;9(12):1520-5 [17099708.001]
  • [Cites] Neurobiol Dis. 2007 Nov;28(2):184-96 [17714952.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):1031-7 [10980141.001]
  • (PMID = 18082964.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096832-01A10004; United States / NCI NIH HHS / CA / CA096832; United States / NINDS NIH HHS / NS / R01 NS044172; United States / NINDS NIH HHS / NS / NS044172; United States / NCI NIH HHS / CA / P01 CA096832-05; United States / NCI NIH HHS / CA / P01 CA096832; United States / NCI NIH HHS / CA / CA096832-05; United States / NCI NIH HHS / CA / P01 CA096832-01A10004
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ NIHMS39023; NLM/ PMC2278004
  •  go-up   go-down


63. Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C: Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol; 2007 Mar;20(3):344-51
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.
  • Reelin is a glycoprotein that plays a critical role in the regulation of neuronal migration during brain development and, since reelin has a role in the control of cell migration, it might represents an important factor in cancer pathology.
  • Stromal tissues, normal epithelial cells and prostate intraepithelial neoplasia (PIN) of any grade around and distant from cancer were always negative for reelin.
  • Our results demonstrated for the first time that reelin is expressed in prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules, Neuronal / biosynthesis. Extracellular Matrix Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Serine Endopeptidases / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277764.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Extracellular Matrix Proteins; 0 / Nerve Tissue Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / reelin protein
  •  go-up   go-down


64. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.
  • The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


65. Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM: Intracranial benign fibrous histiocytomas: a case report and review. J Neurooncol; 2009 Apr;92(2):203-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial benign fibrous histiocytomas: a case report and review.
  • Although there have been several reports about malignant fibrous histiocytomas, less is known about the benign variant of these intracranial tumors as they are often misclassified as other types of tumors.
  • Pathology revealed benign fibrous histiocytoma.
  • We also review other cases reported in the literature in an effort to provide further insight into the diagnosis and management of this rare tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):215-8 [10682930.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):73-6; discussion 76 [16200478.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Oct;30(10 ):759-62 [1708451.001]
  • [Cites] Clin Neuropathol. 2002 May-Jun;21(3):93-8 [12049182.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):284-93 [7681032.001]
  • [Cites] Acta Neuropathol. 1973 Feb 19;23(3):187-99 [4348056.001]
  • [Cites] Surg Neurol. 1988 Jan;29(1):27-31 [3336836.001]
  • [Cites] No Shinkei Geka. 1984 Apr;12 (5):641-8 [6087179.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):157-60 [11508815.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):9-17 [11131990.001]
  • [Cites] No Shinkei Geka. 1991 Mar;19(3):267-71 [2038418.001]
  • (PMID = 19030779.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


66. Baiamonte V, Piccoli F, La Bella V: Dysembryoplastic neuroepithelial tumor of the brainstem. Neuroradiol J; 2008 Apr 07;21(2):209-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumor of the brainstem.
  • Dysembryoplastic neuroepithelial tumor (DNT) is a clinically benign stable lesion, most frequently located in the temporal and frontal lobes, often responsible for epilepsy in young adults.
  • Brain MRI showed a multicystic-like lesion localized in the left inferior pons, involving the ipsilateral cerebellar peduncle and partially dislocating the fourth ventricle.
  • The specific pattern of MRI and CT appearance of DNT and its benign course (our patient is clinically stable with unchanged MRI images at two year follow-up) may help differentiate this tumor from other lesions, i.e. gangliogliomas and glioneural malformations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24256828.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Pasha Q, Malik SA, Shaheen N, Shah MH: Comparison of trace elements in the scalp hair of malignant and benign breast lesions versus healthy women. Biol Trace Elem Res; 2010 May;134(2):160-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of trace elements in the scalp hair of malignant and benign breast lesions versus healthy women.
  • Trace elements including Al, Ca, Cd, Co, Cr, Cu, Fe, K, Mg, Mn, Na, Ni, Pb, Sb, Sr, and Zn were analyzed in the scalp hair samples of women with malignant breast lesions, women with benign breast lesions, and healthy donors using atomic absorption spectrophotometric method.
  • In the scalp hair of malignant-tumor patients, the highest average concentration was shown by Ca (1,187 microg/g), followed by Na (655 microg/g), Mg (478 microg/g), Zn (391 microg/g), Sr (152 microg/g), Fe (114 microg/g), and K (89.8), while in the case of benign-tumor patients, the average estimated element levels were 1,522, 1,093, 572, 457, 217, 80.4, and 74.7 microg/g, respectively.
  • Average levels of Na, Sr, K, Cd, Co, Pb, Mg, Ca, Zn, Ni, Sb, and Mn were revealed to be significantly higher in the hair of malignant and benign patients compared to the healthy women; however, Fe, Cu, Al, and Cr were not significantly different in the scalp hair of the three groups.
  • The quartile distributions of Ca, Cd, Co, Cr, K, Mg, Mn, Na, Ni, Pb, Sb, and Sr revealed maximum spread in the scalp hair of malignant and benign groups; nevertheless, Al, Cu, Fe, and Zn exhibited almost comparable quartile levels in the three groups.
  • Strong correlation coefficients were found between Fe and Cd, Al and Na, Mn and Sr, Co and Cr, Cd and Cr, Pb and K, Pb and Mn, Cu and Na, and Al and Fe in the scalp hair of malignant-tumor patients, while Fe and K, Cd and Co, Na and Co, and Cr and Pb showed strong correlations in the scalp hair of benign-tumor patients, both of which were significantly different compared with the healthy subjects.
  • Multivariate cluster analysis also revealed divergent clustering of the elements in the scalp hair of malignant and benign patients in comparison with the healthy women.
  • [MeSH-major] Brain Neoplasms / metabolism. Hair / chemistry. Scalp / chemistry. Trace Elements / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644659.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trace Elements
  •  go-up   go-down


68. Pui MH, Wang Y: Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children. Clin Imaging; 2005 May-Jun;29(3):162-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children.
  • The purpose of this study was to determine the efficacy of diffusion-weighted imaging (DWI) and magnetization transfer imaging (MTI) in the differential diagnosis of brain infarct, infection, hamartoma, and tumor in 106 children.
  • There was an inverse relationship between ADC and MTR in subacute/chronic infarct, infection, hamartoma, arachnoid cyst, and tumor relative to normal brain parenchyma.
  • DWI and MTI had a complementary role in the differential diagnosis of acute infarct from infection with lower MTR, from hamartoma with higher ADC, and from low-grade gliomas and benign tumors that had higher ADCs and lower MTRs.
  • ADCs increased and MTRs decreased with the duration of infarct and lower tumor grade.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis. Cerebral Infarction / diagnosis. Diffusion Magnetic Resonance Imaging. Image Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855060.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. A da Fonseca M, Thikkurissy S: Maxillary melanotic neuroectodermal tumor of infancy. Int J Clin Pediatr Dent; 2009 Sep;2(3):61-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillary melanotic neuroectodermal tumor of infancy.
  • The melanotic neuroectodermal tumor of infancy (MNTI) is a rare benign neoplasm of neural crest origin most commonly found in the anterior region of the maxilla.
  • The tumor almost always develops during the first year of life, although in some cases it can be present at birth.
  • Main sites for recurrences are the maxilla (57%) and the skull/brain (28.6%).
  • Malignant transformation has been noted in approximately 6.5% of all cases and in 2% of maxillary tumors.
  • The diagnostic and clinico-pathological features as well as tumor management and importance of a timely diagnosis are reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25206125.001).
  • [ISSN] 0974-7052
  • [Journal-full-title] International journal of clinical pediatric dentistry
  • [ISO-abbreviation] Int J Clin Pediatr Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4086571
  • [Keywords] NOTNLM ; Melanotic neuroectodermal tumor of infancy / maxilla / pediatric dentistry / pediatric oral pathology.
  •  go-up   go-down


70. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


71. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


72. Josan V, Smith P, Kornberg A, Rickert C, Maixner W: Development of a pilocytic astrocytoma in a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2007 Jun;106(6 Suppl):509-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a pilocytic astrocytoma in a dysembryoplastic neuroepithelial tumor. Case report.
  • Dysembryoplastic neuroepithelial tumors (DNETs) are benign supratentorial tumors based in the cerebral cortex.
  • When tumors thought to be DNETs are not resected due to their proximity to eloquent cortex, lack of change in the clinical and neuroimaging features over time supports the diagnosis of DNET.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cerebral Cortex. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis


73. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Minniti G, Amichetti M, Enrici RM: Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol; 2009;4:42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and radiosurgery for benign skull base meningiomas.
  • Complex combined surgical approaches are more likely to achieve complete tumor removal, but frequently at a cost of treatment related high morbidity.
  • Local control following subtotal excision of benign meningiomas can be improved with conventional fractionated external beam radiation therapy with a reported 5-year progression-free survival up to 95%.
  • New radiation techniques, including stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (FSRT), and intensity-modulated radiotherapy (IMRT) have been developed as a more accurate technique of irradiation with more precise tumor localization, and consequently a reduction in the volume of normal brain irradiated to high radiation doses.
  • SRS achieves a high tumour control rate in the range of 85-97% at 5 years, although it should be recommended only for tumors less than 3 cm away more than 3 mm from the optic pathway because of high risk of long-term neurological deficits.
  • The reported results indicate a high tumour control rate in the range of 85-100% at 5 years with a low risk of significant incidence of long-term toxicity.
  • Because of the long natural history of benign meningiomas, larger series and longer follow-up are necessary to compare results and toxicity of different techniques.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22 [16029801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1425-30 [16170090.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5):873-86; discussion 873-86 [16284558.001]
  • [Cites] Technol Cancer Res Treat. 2005 Dec;4(6):675-82 [16292888.001]
  • [Cites] Surg Neurol. 2006 Jan;65(1):28-33; discussion 33-4 [16378847.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):28-36; discussion 28-36 [16385326.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 May;64(5):542-8 [16649974.001]
  • [Cites] Radiat Oncol. 2006;1:46 [17173702.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):90-5 [17161483.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):1188-94; discussion 1194 [17277681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):325-36 [17695387.001]
  • [Cites] Neurosurgery. 2007 Aug;61(2):281-6; discussion 286-7 [17762740.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):745-51 [17937218.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:68-73 [11143266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):285-94; discussion 294-6 [11220370.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):325-31 [11483185.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):435-9 [11565865.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Acta Neurochir (Wien). 2001 Nov;143(11):1141-52 [11731865.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E6 [17961043.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):937-44 [17977264.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Prog Neurol Surg. 2009;22:96-111 [18948722.001]
  • [Cites] Can J Neurol Sci. 2002 Aug;29(3):240-8 [12195613.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:71-6 [12379007.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1373-79; discussion 1379-80 [12445342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1473-82 [14508835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1375-83; discussion 1383-4 [15157294.001]
  • [Cites] Radiother Oncol. 2004 Jun;71(3):251-8 [15172139.001]
  • [Cites] Neurosurgery. 1982 Mar;10(3):332-9 [7070635.001]
  • [Cites] J Neurosurg. 1984 Mar;60(3):500-5 [6607981.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1139-43 [6491698.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Neurosurgery. 1989 Jan;24(1):12-7 [2927589.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Acta Neurochir (Wien). 1993;122(1-2):60-70 [8333310.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):245-51 [8027808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):315-21 [7673018.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10 [8587667.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20 [8905745.001]
  • [Cites] Ophthalmology. 1996 Nov;103(11):1761-6; discussion 1766-7 [8942867.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):804-10 [18976068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1324-32 [18922647.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Acta Neurochir (Wien). 2009 Jan;151(1):1-8 [19093071.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1363-70 [11121635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Apr;14(2):103-9 [12069116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):992-1000 [12095568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70 [12128128.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:121-8 [9032852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Acta Neurol Scand. 1997 Nov;96(5):297-304 [9404999.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:19-32 [9782232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] Stereotact Funct Neurosurg. 1998;71(1):43-50 [10072673.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):75-9 [10219797.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):473-80 [10392202.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Nov;61(5):531-43 [15521954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):333-8 [15674748.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • (PMID = 19828022.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2768735
  •  go-up   go-down


75. Nagata S, Jin YF, Yoshizato K, Kitamura M, Iizuka N, Song M, Tomoeda M, Yuki M, Kubo C, Yoshizawa H, Outani H, Hamada K, Araki N, Funauchi M, Tomita Y: Early uptake and continuous accumulation of thallium-201 chloride in a benign mixed tumor of soft tissue: case report. Diagn Pathol; 2010;5:34
Hazardous Substances Data Bank. THALLOUS CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early uptake and continuous accumulation of thallium-201 chloride in a benign mixed tumor of soft tissue: case report.
  • A case of benign mixed tumor of the soft tissue in a 64-year-old Japanese male is presented.
  • The patient underwent a resection of tumor, and the pathological diagnosis was a benign mixed tumor of soft tissue without high vascularity, characterized by histological features similar to pleomorphic adenomas in the salivary glands.
  • Immunohistochemical study proved expression of Na+/K+-ATPase of tumor cells.
  • Overexpression of Na+/K+-ATPase of the tumor might be responsible for the early uptake of Tl-201, and poor vascular structure in this tumor might lead to continuous accumulation.
  • The Tl-201 scintigraphic features of mixed tumor of soft tissue are assessed to resemble those of malignant soft tissue tumors.
  • [MeSH-major] Neoplasms, Complex and Mixed / radionuclide imaging. Radiopharmaceuticals. Soft Tissue Neoplasms / radionuclide imaging. Thallium. Tomography, Emission-Computed

  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):228-35 [11505272.001]
  • [Cites] J Orthop Sci. 2002;7(3):304-12 [12077654.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1183-96 [12960802.001]
  • [Cites] Brain Res. 1989 Feb 20;480(1-2):259-67 [2469513.001]
  • [Cites] Biochem Pharmacol. 1992 Feb 18;43(4):803-7 [1311590.001]
  • [Cites] Am J Physiol. 1994 Feb;266(2 Pt 1):C515-23 [8141265.001]
  • [Cites] Ann Diagn Pathol. 2007 Jun;11(3):190-8 [17498593.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):955-8 [8683319.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):13-22 [8990137.001]
  • [Cites] J Orthop Sci. 1998;3(6):297-303 [9811980.001]
  • [Cites] Virchows Arch. 1999 May;434(5):393-400 [10389622.001]
  • [Cites] Dentomaxillofac Radiol. 2005 Jul;34(4):212-7 [15961594.001]
  • [Cites] Ann Nucl Med. 2005 Sep;19(6):461-8 [16248382.001]
  • [Cites] J Cell Physiol. 1994 Jul;160(1):113-20 [8021291.001]
  • (PMID = 20509963.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  • [Other-IDs] NLM/ PMC2887811
  •  go-up   go-down


76. Tuniz F, Soltys SG, Choi CY, Chang SD, Gibbs IC, Fischbein NJ, Adler JR Jr: Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery; 2009 Nov;65(5):898-907; discussion 907
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study.
  • OBJECTIVE: Although radiosurgery plays an important role in managing benign cranial base lesions, the potential for increased toxicity with single-session treatment of large tumors is a concern.
  • In this retrospective study, we report the intermediate-term rate of local control, morbidity, and clinical outcomes of patients with large cranial base tumors treated with multisession stereotactic radiosurgery with the CyberKnife (Accuray, Inc., Sunnyvale, CA).
  • METHODS: Between 1999 and 2008, 34 consecutive patients with large (>15 cm), benign cranial base tumors (21 meningiomas, 9 schwannomas, 4 glomus jugulare tumors) underwent primary or postoperative radiosurgical treatment using a multisession approach at Stanford University and were considered in this retrospective study.
  • CyberKnife radiosurgery was delivered in 2 to 5 sessions (median, 3 sessions) to a median tumor volume of 19.3 cm (range, 15.8-69.3 cm).
  • To date, all tumors remain locally controlled.
  • CONCLUSION: Over our modest length of follow-up, multisession radiosurgery appears to be a safe and effective option for selected large, benign brain and cranial base lesions.
  • [MeSH-major] Radiosurgery / methods. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834402.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology; 2007 Oct;27(5):407-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
  • We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas.
  • We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied.
  • There was no dependable histological parameter to predict recurrence among benign-looking meningiomas.
  • The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas.
  • In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339).
  • Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas.
  • MIB-1 positive tumor cells were maximally aggregated at the periphery of excised specimen.
  • MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.
  • [MeSH-major] Biomarkers / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Brain Neoplasms / pathology. Humans. Mitotic Index. Neoplasm Invasiveness. Probability. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018472.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


78. Gal TJ, Shinn J, Huang B: Current epidemiology and management trends in acoustic neuroma. Otolaryngol Head Neck Surg; 2010 May;142(5):677-81
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study was to assess the epidemiology of acoustic neuroma and determine current trends in therapy using tumor registry techniques.
  • SUBJECTS AND METHODS: The Surveillance Epidemiology and End Results (SEER) database is a national tumor registry that began to identify and abstract benign and borderline tumors of the brain and central nervous system in the year 2004.
  • Demographic data, tumor size, and treatment data were analyzed.
  • Tumors were equally distributed across gender and tumor laterality, with the majority (84%) occurring in Caucasians.
  • Of tumors less than 2 cm, 27.2 percent were treated with radiotherapy.
  • Statistically significant associations were observed with the increased use of radiotherapy for small (< 2 cm) tumors (P = 0.0001).

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20416455.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


80. Skardelly M, Armbruster FP, Meixensberger J, Hilbig H: Expression of Zonulin, c-kit, and Glial Fibrillary Acidic Protein in Human Gliomas. Transl Oncol; 2009 Aug 18;2(3):117-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because angiogenesis and tumor invasion have been associated with extracellular matrix degradation and intercellular tight junctions, the involvement of zonulin in glioma biology is in the focus.
  • The meningioma WHO I is regarded as benign, whereas the meningioma WHO III is recognized as the transition form of malignant tumors in humans.
  • The visualization of a newly designed antibody against human zonulin was studied in triple-labeling studies using fluorescence immunocytochemistry and compared with the expression of c-kit and glial fibrillary acidic protein in differently developed human gliomas.
  • We found that increasing the expression of c-kit is accompanied by an increase of zonulin expression.
  • Both are correlated to the degree of malignancy of human brain tumors.
  • The expression of zonulin is correlated to the degradation of the blood-brain barrier as revealed by Griffonia simplicifolia lectin.
  • In differently graded tumors, we found differently graded involvement of blood vessels in the tumor development, explaining patients' survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2006 Apr;41(4):408-19 [16635908.001]
  • [Cites] Clin Neuropathol. 2006 May-Jun;25(3):107-14 [16719406.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):163-7 [16132509.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):195-202 [16132504.001]
  • [Cites] J Clin Invest. 1989 Feb;83(2):724-7 [2492310.001]
  • [Cites] J Clin Invest. 1989 Apr;83(4):1089-94 [2649511.001]
  • [Cites] Infect Immun. 2003 Apr;71(4):1897-902 [12654806.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1607-15 [12404235.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:214-22 [11193578.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19160-5 [11278543.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 24:4435-40 [11082037.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Nov;24(6):687-91 [19122516.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • (PMID = 19701495.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730142
  •  go-up   go-down


81. Kim MS, Muratore C, Snelling L, Mandelbaum DE, McEachern R, Mangray S, Faizan M, Quintos JB: Ischemic stroke and rhabdomyolysis in a 15-year-old girl with paraganglioma due to an SDHB exon 6 (Q214X) mutation. J Pediatr Endocrinol Metab; 2009 Jun;22(6):565-71
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report a 15-year-old girl with a recent diagnosis of type 2 diabetes mellitus who presented in malignant hypertensive crisis (BP 210/120 mm Hg).
  • RESULTS: Pathology showed a Zellballen pattern, negative tumor margins and benign para-aortic lymph nodes.
  • Mutation analysis of the succinate dehydrogenase type B (SDHB) gene revealed a heterozygous change of C to T at position 640 in exon 6 (Q214X) predicting an amino acid change to a stop codon.
  • [MeSH-major] Brain Ischemia / etiology. Germ-Line Mutation. Paraganglioma, Extra-Adrenal / genetics. Retroperitoneal Neoplasms / genetics. Rhabdomyolysis / etiology. Stroke / etiology. Succinate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Ischemic stroke.
  • Genetic Alliance. consumer health - Rhabdomyolysis.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694205.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


82. Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL: Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther; 2009 Dec;16(12):1477-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In benign prostate tissues, G207 and G47Delta titers were notably reduced, whereas strain F titers were maintained at similar levels compared with prostate cancer specimens.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Apr;74(8):3832-41 [10729157.001]
  • [Cites] Nat Rev Microbiol. 2008 Jul;6(7):529-40 [18552863.001]
  • [Cites] Urology. 2000 Jul;56(1):160-6 [10869659.001]
  • [Cites] Rev Med Virol. 2000 Sep-Oct;10(5):305-19 [11015742.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5714-22 [11059765.001]
  • [Cites] Hum Gene Ther. 2000 Dec 10;11(18):2465-72 [11119418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401 [11353831.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):451-6 [11687957.001]
  • [Cites] Dev Biol. 2004 Mar 15;267(2):387-98 [15013801.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5199-207 [7693334.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] J Virol. 1997 Aug;71(8):6049-54 [9223497.001]
  • [Cites] J Virol. 1998 Sep;72(9):7005-11 [9696792.001]
  • [Cites] J Virol. 1998 Sep;72(9):7064-74 [9696799.001]
  • [Cites] Hum Gene Ther. 1999 Sep 1;10(13):2237-43 [10498254.001]
  • [Cites] Gene Ther. 1999 Oct;6(10):1751-8 [10516725.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1532-40 [15735042.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1257-68 [15824085.001]
  • [Cites] Cancer Gene Ther. 2006 Mar;13(3):253-65 [16179929.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1193-5 [16879022.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):103-13 [17164781.001]
  • [Cites] J Virol. 2007 Apr;81(7):3455-64 [17229694.001]
  • [Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]
  • [Cites] FASEB J. 2008 Jun;22(6):1839-48 [18234972.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • (PMID = 19693098.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102139-06A1; United States / NCI NIH HHS / CA / R01 CA102139; United States / NCI NIH HHS / CA / R01 CA102139-06A1
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS180783; NLM/ PMC2836587
  •  go-up   go-down


83. Lu-Emerson C, Plotkin SR: The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis; 2009;6(2):E47-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatoses, including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis, comprise a group of genetically distinct disorders of the nervous system unified by the predisposition to nerve sheath tumors.
  • NF1 is the most common neurogenetic disorder, with a birth incidence of 1 in 3000.
  • The hallmark lesion of NF1 is the neurofibroma, a benign tumor derived from the nerve sheath and composed of a mixture of proliferating Schwann cells, fibroblasts, mast cells, and pericytes.
  • [MeSH-major] Bone and Bones / pathology. Nervous System / pathology. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / genetics. Skin / pathology
  • [MeSH-minor] Brain / pathology. Brain / physiopathology. Cafe-au-Lait Spots / genetics. Cafe-au-Lait Spots / pathology. Cafe-au-Lait Spots / physiopathology. Eye / pathology. Eye / physiopathology. Genes, Tumor Suppressor / physiology. Humans. Neurofibromatoses / genetics. Neurofibromatoses / pathology. Neurofibromatoses / physiopathology. Peripheral Nervous System / pathology. Peripheral Nervous System / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587630.001).
  • [ISSN] 1949-4378
  • [Journal-full-title] Reviews in neurological diseases
  • [ISO-abbreviation] Rev Neurol Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


84. Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, Flickinger JC: Stereotactic radiosurgery for convexity meningiomas. J Neurosurg; 2009 Sep;111(3):458-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Meningiomas of the cerebral convexity are often surgically curable because both the mass and involved dura mater can be removed.
  • Tumors were located in frontal (80 patients), parietal (24 patients), temporal (12 patients), and occipital (9 patients) areas.
  • The WHO tumor grades in patients with prior resections were Grade I in 34 patients, Grade II in 15 patients, and Grade III in 6 patients.
  • Seventy patients underwent primary radiosurgery and therefore had no prior histological tumor diagnosis.
  • The mean tumor volume was 7.6 ml.
  • Radiosurgery was performed using the Leksell Gamma Knife with a mean tumor margin dose of 14.2 Gy.
  • After primary radiosurgery, the tumor control rate was 92%.
  • After adjuvant radiosurgery, the control rate was 97% for Grade I tumors.
  • The actuarial tumor control rates at 3 and 5 years for the entire series were 86.1+/-3.8% and 71.6+/-8.6%, respectively.
  • For patients with benign tumors (Grade I) and those without prior surgery, the actuarial tumor control rate was 95.3+/-2.3% and 85.8+/-9.3%, respectively.
  • No patient developed a subsequent radiation-induced tumor.
  • CONCLUSIONS: Stereotactic radiosurgery provides satisfactory control rates either after resection or as an alternate to resection, particularly for histologically benign meningiomas.
  • Its role is most valuable for patients whose tumors affect critical neurological regions and who are poor candidates for resection.
  • Both temporary and permanent morbidity are related to brain location and tumor volume.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Female. Humans. Male. Neurofibromatosis 2 / complications. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199473.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Lee DK, Cho KT, Im SH, Hong SK: Pleomorphic xanthoastrocytoma with an intracystic hemorrhage : a case report and literature review. J Korean Neurosurg Soc; 2007 Nov;42(5):410-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) has been considered as a low grade tumor of adolescents and young adults.
  • Although this tumor often shows cystic component, the hemorrhage within the cyst is extremely rare.
  • After gross total resection of the tumor, the patient was fully recovered from neurological deficit.
  • It is suggested that this typically benign tumor could be presented with hemorrhage, causing a rapid neurological deterioration.
  • Prompt surgical intervention, especially total removal of the tumor can provide an excellent functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1397-404 [8279337.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):353-5 [1513442.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):1079-82; discussion 1082 [12234421.001]
  • [Cites] Br J Radiol. 2001 Mar;74(879):270-2 [11338106.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):169-71 [15690134.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):154-6 [8770268.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):564-9 [8113873.001]
  • (PMID = 19096580.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588191
  • [Keywords] NOTNLM ; Cyst / Hemorrhage / Mural nodule / Pleomorphic xanthoastrocytoma (PXA)
  •  go-up   go-down


86. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening brain magnetic resonance (MR) imaging with gadolinium had detected multiple homogeneously enhanced tumors in the right convexity and in the anterior and posterior thirds of the falx cerebri after surgery for osteosarcoma in his right leg at age 52 years.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • Patients with meningioma associated with Werner syndrome should be carefully followed up to detect the occurrence of other extracranial tumors such as sarcoma by brain MR imaging, echography, or body computed tomography.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Werner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948683.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Gu TF, Xiao XL, Sun F, Yin JH, Zhao H: Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. Chin Med Sci J; 2008 Sep;23(3):145-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases.
  • OBJECTIVE: To evaluate the values of whole body diffusion weighted imaging (DWI) in screening primary unknown tumor in patients with metastases.
  • METHODS: Totally, 34 patients with metastases of primary unknown tumors were scanned with whole body DWI, and conventional magnetic resonance (MR) imaging was performed if suspected lesions were detected.
  • All the metastases including 27 cases of osseous metastases, 2 brain metastases, 2 liver metastases, 1 pulmonary multiple metastasis, 1 neck metastasis and 1 malignant ascites, were diagnosed by computed tomography, single photon emission computed tomography, or MR imaging.
  • For the proven primary tumors diagnosed by biopsy or pathology of surgical specimens, apparent diffusion coefficient (ADC) values of the primary and metastatic lesions were measured respectively.
  • The sensitivity and specificity of this technique for screening primary tumors were evaluated.
  • RESULTS: We found 24 cases with suspected primary lesions, in which 23 lesions were proved to be primary tumors, and 1 was proved to be benign lesion.
  • And no definite primary lesion was found in 10 cases on whole body DWI, but in which 1 case was diagnosed with primary tumor by biopsy later, and the other 9 cases remained unknown within follow-up of over half a year.
  • The sensitivity and specificity of whole body DWI for searching primary tumors was 95.8% and 90.0%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853848.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Morokoff AP, Zauberman J, Black PM: Surgery for convexity meningiomas. Neurosurgery; 2008 Sep;63(3):427-33; discussion 433-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas that occur over the convexity of the brain are the most common meningiomas, but little has been published about their contemporary management.
  • RESULTS: Convexity tumors represented 22% of all meningiomas operated on.
  • The pathology of the tumors was benign in 144 (88.3%), atypical in 16 (9.8%), and anaplastic/malignant in 3 (1.8%).
  • In six of the cases designated "benign," there were borderline atypical features.
  • The 5-year recurrence rate for benign meningiomas was 1.8%, atypical meningiomas 27.2%, and anaplastic meningiomas 50%.
  • The two cases of benign tumor recurrences involved tumors with borderline atypia and high MIB-1 indices.
  • The borderline atypical cases had a 5-year recurrence-free survival rate of only 55.9%, more closely approximating that of tumors designated "atypical."
  • Benign convexity meningiomas having a Simpson Grade I complete excision have a very low recurrence rate.
  • The recurrence rates of atypical and malignant tumors are significantly higher, and borderline atypical tumors should be considered to behave more like atypical rather than benign lesions.
  • Longer-term follow-up data are needed to more accurately determine the recurrence rates of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Craniotomy / methods. Craniotomy / mortality. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812953.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Rodriguez FJ, Scheithauer BW, Roncaroli F, Silva AI, Kovacs K, Brat DJ, Jin L: Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study. Am J Surg Pathol; 2008 Sep;32(9):1344-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study.
  • We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases).
  • Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test).
  • Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged.
  • Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Galectin 3 / biosynthesis. Nerve Sheath Neoplasms / metabolism. Sella Turcica / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670355.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


90. Saito R, Kumabe T, Watanabe M, Jokura H, Shibuya M, Nakazato Y, Tominaga T: Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg; 2008 Apr;108(4):798-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The low-grade fibromyxoid sarcoma is a rare sarcoma of the deep soft tissue that is characterized as an indolent but metastasizing soft-tissue neoplasm with a deceptively benign histological appearance.
  • A high rate of local recurrence and eventual metastasis has been demonstrated for this tumor in deep soft tissue.
  • The tumor is still under control without any evidence of extracranial metastasis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Radiosurgery. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377261.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol; 2008 Apr;128(4):980-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive.
  • These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions.
  • The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner.
  • [MeSH-major] Melanoma / enzymology. Melanoma / pathology. Protein Kinases / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. DNA Mutational Analysis. Humans. Nevus / enzymology. Nevus / pathology. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Ribosomal Protein S6 / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914450.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


92. Bougrine F, Bacha D, Chouchane O, Laabidi B, Yeades M, Bouziani A: [Intracerebral schwannoma: case report]. Neurochirurgie; 2007 Nov;53(5):387-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was removed through a right parietal craniotomy.
  • The most popular hypothesis argues that these tumors arise from the proliferation of Schwann cells in the perivascular nerve plexii.
  • CONCLUSIONS: Intracerebral schwannoma is an extremely rare benign tumor.
  • The importance of recognizing this tumor is stressed, particularly in younger patients, given its benign nature, radiological resemblance to other tumors and favorable response to resection without toxic treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neurosurgical Procedures. Seizures / etiology

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884108.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol; 2007 Oct;9(4):447-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for the use of radiotherapy in the management of a variety of benign intracranial neoplastic and nonneoplastic pathologies are increasing.
  • Although the short-term risks are minimal, the long-term risks of radiation-induced de novo secondary neoplasms or malignant progression of the primary benign tumor need to be considered.
  • There are currently 19 reported cases of tumors linked with stereotactic radiotherapy/radiosurgery, to which we add our second institutional experience of a patient who succumbed to a glioblastoma multiforme (GBM) after stereotactic radiotherapy for an acoustic neuroma (AN).
  • Review of these 20 cases revealed 10 de novo secondary tumors, of which eight were malignant, with six being malignant gliomas.
  • Accelerated growth of the primary benign AN, some 2 to 6 years after focused radiotherapy, was found in six of eight NF2 patients, with pathological verification of a malignant nerve sheath tumor documented in most.
  • [MeSH-major] Brain Neoplasms / etiology. Glioblastoma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroma, Acoustic / surgery. Radiosurgery / adverse effects

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:2-10 [10681685.001]
  • [Cites] Otol Neurotol. 2006 Feb;27(2):213-9 [16436992.001]
  • [Cites] Am J Otol. 2000 May;21(3):364-70 [10821550.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):93-5 [10889878.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):948-50 [12160289.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):296-307; discussion 307-8 [12535357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1291-6; discussion 1296-7 [12762874.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Aug;46(4):254-6 [14506573.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jan;44(1):29-32 [14959934.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):301-5 [15015661.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):414-20 [15179297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6541-7 [15221010.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1274-82 [3815303.001]
  • [Cites] N Engl J Med. 1990 Jul 12;323(2):127-9 [2359422.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Tumori. 1992 Apr 30;78(2):143-6 [1523707.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):653-8 [9761063.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1008-14 [10070956.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):335-49 [15527099.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):271-3 [16226702.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • (PMID = 17704364.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994102
  •  go-up   go-down


94. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


95. Baggenstos MA, Butman JA, Oldfield EH, Lonser RR: Role of edema in peritumoral cyst formation. Neurosurg Focus; 2007;22(5):E9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritumoral cysts (those arising immediately adjacent to the tumor mass) are frequently associated with benign and malignant tumors of the brain and spinal cord (syringomyelia).
  • The cystic component of central nervous system (CNS) tumors and associated peritumoral cysts are often the cause of clinical symptoms.
  • Because of the common occurrence of peritumoral cysts with CNS neoplasms and the morbidity associated with them, advanced imaging, histological, and molecular techniques have been used to determine the mechanism underlying cyst formation and propagation.
  • Mediators of vascular permeability acting locally in the tumor and/or hydrodynamic forces within abnormal tumor vasculature appear to drive fluid extravasation.
  • These findings support the concept that the tumor itself is the source of the edema that precedes cyst formation and that resection of tumors or medical therapies directed at decreasing their vascular permeability will result in the resolution of edema and cysts.
  • [MeSH-major] Brain Edema / etiology. Brain Edema / pathology. Brain Neoplasms / complications. Central Nervous System Cysts / complications
  • [MeSH-minor] Blood-Brain Barrier / drug effects. Blood-Brain Barrier / physiopathology. Diagnostic Imaging. Humans. Neovascularization, Pathologic. Spinal Cord Diseases / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613240.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


96. Takahashi H, Harada M, Kimura M, Kato H: Thymolipoma combined with hyperthyroidism discovered by neurological symptoms. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):114-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymolipomas are rare slow-growing mediastinal thymic neoplasms.
  • Central nervous system disorder was suggested but no significant abnormalities were found on brain MR nor were there any neurological signs.
  • Several months later, neurological and systemic examinations on admission revealed hyperthyroidism and an anterior mediastinal tumor, 9.0x5.0x3.0 cm in size on chest CT films.
  • Neurologists recommended resection of the mediastinal tumor.
  • Malignancy could not be ruled out because of the irregularity of the tumor appearance on contrast-enhanced chest CT.
  • Furthermore, the tumor appeared to be attached to the ascending aorta, so cytological and/or pathological diagnosis by CT-guided needle biopsy before operation were contraindicated.
  • The pathological diagnosis was benign thymolipoma consisting of mature fatty tissue and thymic tissue structures with Hassall's corpuscles.
  • [MeSH-major] Hyperthyroidism / complications. Lipoma / complications. Thymus Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505419.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Bookland MJ, Bagley CA, Schwarz J, Burger PC, Brem H: Intracavernous trigeminal ganglion amyloidoma: case report. Neurosurgery; 2007 Mar;60(3):E574; discussion E574
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To the authors' knowledge, there have been 52 documented cases of primary amyloid tumors of the central nervous system and closely associated structures.
  • Brain magnetic resonance imaging was acquired, demonstrating abnormal contrast enhancement and enlargement of the right trigeminal ganglion.
  • With the site of the tumor within the cavernous sinus verified by pathology, the remainder of the tumor was removed.
  • A final pathological review of the resected tumor confirmed a diagnosis of amyloidoma of the trigeminal ganglion.
  • Even in the absence of systemic signs of amyloidosis, this benign protein deposition disease should be considered in the differential for atypical dysesthesias of the trigeminal dermatomes.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327767.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


99. Reddy JS, Mishra AM, Behari S, Husain M, Gupta V, Rastogi M, Gupta RK: The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol; 2006 Sep;66(3):246-50; discussion 250-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions.
  • BACKGROUND: The objective of this study is to evaluate the sensitivity and specificity of DWI in differentiating brain abscesses from other intracranial cystic lesions.
  • Lesions appearing hyperintense on DWI with the ADC values of lower than 0.9 +/- 0.13 x 10(-3) mm(2)/s (mean +/- SD) were considered as brain abscess, whereas hypointense lesions on DWI with the ADC values 2.2 +/- 0.9 x 10(-3) mm(2)/s were categorized as nonabscess cystic lesions.
  • RESULTS: Ninety-three of 97 brain abscess lesions were hyperintense on DWI, with significantly low (P = .0001) ADC value (0.87 +/- 0.05 x 10(-3) mm(2)/s) (mean +/- SEM), compared with 48 nonabscess lesions (2.89 +/- 0.05 x 10(-3) mm(2)/s).
  • Four of 97 brain abscess lesions in 65 patients were false negative, and 2 of 50 nonabscess lesions in 50 patients were false positive for the diagnosis of brain abscess.
  • The ADC value of the tumor cysts (2.9 +/- 0.05 x 10(-3) mm(2)/s) was significantly lower (P = .02) compared with benign cysts and neurocysticercosis (3.2 +/- 0.05 x 10(-3) mm(2)/s) among nonabscess group.
  • The sensitivity of DWI for the differentiation of brain abscesses from nonabscesses was 96%; specificity, 96%; positive predictive value, 98%; negative predictive value, 92%; and accuracy of the test, 96%.
  • CONCLUSIONS: Diffusion-weighted imaging has high sensitivity and specificity for the differentiation of brain abscess from other nonabscess intracranial cystic lesions.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Central Nervous System Cysts / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Body Water / metabolism. Brain / pathology. Child. Child, Preschool. Diagnosis, Differential. Diffusion. Female. Humans. Infant. Male. Middle Aged. Nerve Fibers, Myelinated / metabolism. Nerve Fibers, Myelinated / pathology. Predictive Value of Tests. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935625.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Kobayashi H, Ishii N, Murata J, Saito H, Kubota KC, Nagashima K, Iwasaki Y: Cystic meningioangiomatosis. Pediatr Neurosurg; 2006;42(5):320-4
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of cerebral meningioangiomatosis with rare cyst formation is reported.
  • The tumor was located in the leptomeninges and cerebral cortex.
  • It is important to distinguish meningioangiomatosis from other possible cortical lesions and epileptic foci should be carefully considered before resection, because it is a benign and surgically manageable cause of seizures.
  • [MeSH-major] Angiomatosis / surgery. Brain Diseases / surgery. Cerebral Cortex / surgery. Meninges / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902347.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement